Search

KP-1461

KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue.

Picrotoxin

Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]

Streptococcus pneumoniae type 3 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 3 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae*

Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

Mefloquine

Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. … It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche.

Serelaxin

bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy. … Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic

Bentonite

N,N'-diphenyl-1,4-phenylenediamine

Pimavanserin

In fact, pimavanserin is the first antipsychotic drug without D₂ blocking activity. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized

Binimetinib

[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients … Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].